Loading
A phase 3 trial of Capivasertib and Fulvestrant in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients is a phase 3 interventional study registered as NCT06635447 by AstraZeneca, with 293 participants enrolled, started 2024-09-26 and due to reach its primary completion in 2026-10-31. Interventions recorded: Capivasertib and Fulvestrant.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PI3K, AKT and mTOR inhibitors, Capivasertib, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Capivasertib, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/